AR047509A1 - Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2 - Google Patents
Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2Info
- Publication number
- AR047509A1 AR047509A1 ARP050100205A ARP050100205A AR047509A1 AR 047509 A1 AR047509 A1 AR 047509A1 AR P050100205 A ARP050100205 A AR P050100205A AR P050100205 A ARP050100205 A AR P050100205A AR 047509 A1 AR047509 A1 AR 047509A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- optionally substituted
- sulfonamide derivatives
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a derivados de sulfonamida como antagonistas de receptores adrenérgicos beta 2, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y usos para trastornos y afecciones inflamatorias, alérgicas y respiratorias. Reivindicacion 1: Un compuesto de formula general (1) en la que el grupo (CH2)n-C(=O)Q1 está en posicion meta o para, R1 y R2 se seleccionan independientemente entre H y alquilo C1-4, n es 0, 1 o 2 y Q1 es un grupo seleccionado entre las formulas (2) o (3) y un grupo *-NR8-Q2-A, donde p es 1 o 2; Q2 es un alquileno C1-4 opcionalmente sustituido con un grupo hidroxi, R8 es H o alquilo C1-4 y A es piridilo opcionalmente sustituido con OH, cicloalquilo C3-7 opcionalmente sustituido con OH o un grupo de formula (4) o (5) en el que R3, R4, R5, R6 y R7 son iguales o diferentes y se seleccionan entre H, alquilo C1-4, OR9, SR9, halo, CN, CF3, OCF3, COOR9, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 y fenilo opcionalmente sustituido con 1 a 3 grupos seleccionados entre OR9, halo y alquilo C1-4, donde R9 y R10 son iguales o diferentes y se seleccionan entre H o alquilo C1-4 y el * representa el punto de union al grupo carbonilo; donde el grupo Q1 está sustituido al menos con un grupo hidroxi; o, si es apropiado, sus sales farmacéuticamente aceptables y/o isomeros, tautomeros, solvatos o variaciones isotopicas de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290169 | 2004-01-22 | ||
| GB0406387A GB0406387D0 (en) | 2004-03-22 | 2004-03-22 | Sulfonamide derivatives for the treatment of diseases |
| US60026004P | 2004-08-09 | 2004-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047509A1 true AR047509A1 (es) | 2006-01-25 |
Family
ID=36954179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100205A AR047509A1 (es) | 2004-01-22 | 2005-01-20 | Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US7244766B2 (es) |
| EP (1) | EP1708991B1 (es) |
| JP (1) | JP4020954B2 (es) |
| AP (1) | AP2359A (es) |
| AR (1) | AR047509A1 (es) |
| AT (1) | ATE375977T1 (es) |
| AU (1) | AU2005214153B2 (es) |
| BR (1) | BRPI0507085A (es) |
| CA (1) | CA2553789C (es) |
| DE (1) | DE602005002930T2 (es) |
| DK (1) | DK1708991T3 (es) |
| DO (1) | DOP2005000006A (es) |
| EA (1) | EA011167B1 (es) |
| ES (1) | ES2293530T3 (es) |
| GE (1) | GEP20094781B (es) |
| MY (1) | MY143390A (es) |
| NL (1) | NL1028087C2 (es) |
| NO (1) | NO20062983L (es) |
| NZ (1) | NZ548318A (es) |
| OA (1) | OA13362A (es) |
| PA (1) | PA8622001A1 (es) |
| PE (1) | PE20051136A1 (es) |
| PL (1) | PL1708991T3 (es) |
| PT (1) | PT1708991E (es) |
| RS (1) | RS50561B (es) |
| SI (1) | SI1708991T1 (es) |
| TW (1) | TWI341831B (es) |
| UA (1) | UA84048C2 (es) |
| UY (1) | UY28721A1 (es) |
| WO (1) | WO2005080313A2 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548318A (en) * | 2004-01-22 | 2009-03-31 | Pfizer | Sulfonamide derivatives for the treatment of diseases |
| GB0425054D0 (en) * | 2004-03-23 | 2004-12-15 | Pfizer Ltd | Formamide derivatives for the treatment of diseases |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| EP1695973A1 (en) * | 2005-02-24 | 2006-08-30 | Neuro3D | Ocaperidone salt and pharmaceutical compositions containing the same |
| WO2007010356A2 (en) * | 2005-07-18 | 2007-01-25 | Pfizer Limited | Process for the preparation of sulfonamide derivatives |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| JP4948913B2 (ja) * | 2006-06-16 | 2012-06-06 | 上野製薬株式会社 | ナフタレンカルボン酸アミドの製造方法 |
| WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| PL2379507T3 (pl) | 2008-12-30 | 2014-03-31 | Pulmagen Therapeutics Inflammation Ltd | Związki sulfonamidu do leczenia zaburzeń układu oddechowego |
| AU2010252609A1 (en) | 2009-05-29 | 2011-11-10 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| JP5801997B2 (ja) | 2009-07-07 | 2015-10-28 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器 |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| WO2013021309A1 (en) | 2011-08-11 | 2013-02-14 | Pfizer Limited | Intermediate and process for the preparation of a sulfonamide derivative |
| CN116033893A (zh) | 2020-06-26 | 2023-04-28 | 迈兰制药英国有限公司 | 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US229058A (en) * | 1880-06-22 | spencer | ||
| US143034A (en) * | 1873-09-23 | Improvement in rocking-grates | ||
| US4404224A (en) | 1981-12-02 | 1983-09-13 | American Cyanamid Company | Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals |
| US4540581A (en) * | 1984-01-31 | 1985-09-10 | Bristol-Myers Company | Topical nonsteroidal anti-inflammatory compositions and uses |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5264067A (en) | 1992-04-23 | 1993-11-23 | Geber Garment Technology, Inc. | Adjustable length carriage compatible for use with differing spreading table widths and types |
| US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| JPH10218861A (ja) | 1997-02-04 | 1998-08-18 | Yamanouchi Pharmaceut Co Ltd | 新規なフェネタノール誘導体又はその塩 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0995742A4 (en) * | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| HRP20000765A2 (en) * | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
| US7048994B2 (en) | 2001-02-23 | 2006-05-23 | Teijin Limited | Laminated polyester film and magnetic recording medium |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| DE10244972B4 (de) * | 2002-03-26 | 2013-02-28 | The Japan Steel Works, Ltd. | Wärmefester Stahl und Verfahren zur Herstellung desselben |
| JP2005527618A (ja) * | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト |
| EP1477167A1 (en) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| NZ548318A (en) * | 2004-01-22 | 2009-03-31 | Pfizer | Sulfonamide derivatives for the treatment of diseases |
-
2005
- 2005-01-12 NZ NZ548318A patent/NZ548318A/en not_active IP Right Cessation
- 2005-01-12 SI SI200530103T patent/SI1708991T1/sl unknown
- 2005-01-12 EA EA200601223A patent/EA011167B1/ru not_active IP Right Cessation
- 2005-01-12 AT AT05702252T patent/ATE375977T1/de active
- 2005-01-12 PL PL05702252T patent/PL1708991T3/pl unknown
- 2005-01-12 WO PCT/IB2005/000086 patent/WO2005080313A2/en not_active Ceased
- 2005-01-12 AU AU2005214153A patent/AU2005214153B2/en not_active Ceased
- 2005-01-12 RS RSP-2007/0488A patent/RS50561B/sr unknown
- 2005-01-12 CA CA2553789A patent/CA2553789C/en not_active Expired - Fee Related
- 2005-01-12 DE DE602005002930T patent/DE602005002930T2/de not_active Expired - Lifetime
- 2005-01-12 OA OA1200600234A patent/OA13362A/en unknown
- 2005-01-12 DK DK05702252T patent/DK1708991T3/da active
- 2005-01-12 PT PT05702252T patent/PT1708991E/pt unknown
- 2005-01-12 AP AP2006003669A patent/AP2359A/xx active
- 2005-01-12 BR BRPI0507085-6A patent/BRPI0507085A/pt not_active IP Right Cessation
- 2005-01-12 EP EP05702252A patent/EP1708991B1/en not_active Expired - Lifetime
- 2005-01-12 UA UAA200608227A patent/UA84048C2/ru unknown
- 2005-01-12 GE GEAP20059536A patent/GEP20094781B/en unknown
- 2005-01-12 JP JP2006550327A patent/JP4020954B2/ja not_active Expired - Fee Related
- 2005-01-12 ES ES05702252T patent/ES2293530T3/es not_active Expired - Lifetime
- 2005-01-18 TW TW094101443A patent/TWI341831B/zh not_active IP Right Cessation
- 2005-01-18 MY MYPI20050197A patent/MY143390A/en unknown
- 2005-01-19 US US11/038,452 patent/US7244766B2/en not_active Expired - Fee Related
- 2005-01-19 UY UY28721A patent/UY28721A1/es not_active Application Discontinuation
- 2005-01-20 DO DO2005000006A patent/DOP2005000006A/es unknown
- 2005-01-20 AR ARP050100205A patent/AR047509A1/es unknown
- 2005-01-20 PE PE2005000079A patent/PE20051136A1/es not_active Application Discontinuation
- 2005-01-21 NL NL1028087A patent/NL1028087C2/nl not_active IP Right Cessation
- 2005-01-21 PA PA20058622001A patent/PA8622001A1/es unknown
-
2006
- 2006-06-27 NO NO20062983A patent/NO20062983L/no not_active Application Discontinuation
-
2007
- 2007-07-03 US US11/772,995 patent/US7528170B2/en not_active Expired - Fee Related
-
2009
- 2009-04-08 US US12/420,206 patent/US7767715B2/en not_active Expired - Fee Related
-
2010
- 2010-07-01 US US12/828,762 patent/US8013019B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047509A1 (es) | Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2 | |
| AR047510A1 (es) | Derivados de sulfonamida como agonistas de receptores adrenergicos ??2 | |
| AR044475A1 (es) | Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades | |
| AR044476A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR053344A1 (es) | Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR081337A1 (es) | Derivados de 1,4-benzotiazepinas, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de trastornos metabolicos | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| AR044005A1 (es) | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| UY27322A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
| AR075050A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |